Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR3 | O15455 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065909 | 1.00 | TLR3 (0.59) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL3193294 | 0.87 | TLR3 (0.59) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL11151641 | 0.74 | TLR3 (0.49) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL2887363 | 0.74 | CYP1A2 (0.59) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL10347885 | 0.74 | TLR3 (0.49) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL13476237 | 0.74 | ALDH1A1 (0.57) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL8680604 | 0.73 | MAPT (0.60) | TLR3HIF1AEPAS1ALDH1A1HPGD | |
| SCHEMBL27810644 | 0.73 | ODC1 (0.45) | TLR3HIF1AEPAS1ALDH1A1CA9 | |
| SCHEMBL7299822 | 0.73 | AKR1B1 (0.43) | TLR3HIF1AALDH1A1CA9CA12 | |
| SCHEMBL20718982 | 0.73 | HTR2C (0.54) | TLR3HIF1AEPAS1ALDH1A1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | SPARK BIOPHARMA, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| CN-1934116-B | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD | 2012-10-10 | — | — | CN | disclosed |
| CN-101437827-B | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD | 2012-08-29 | — | — | CN | disclosed |
| CN-1980910-B | Benzopyran compound for treating arrhythmia | NISSAN CHEMICAL IND LTD | 2012-06-13 | — | — | CN | disclosed |
| CN-101429200-B | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2012-05-30 | — | — | CN | disclosed |
| WO-2011007877-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE EPOXY COMPOUND, LIGAND USED IN THE METHOD, COMPLEX, METHOD FOR PRODUCING THE LIGAND, AND METHOD FOR PRODUCING THE COMPLEX | 日産化学工業株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
| WO-1990012011-A1 | NOVEL ANTIHYPERTENSIVE BENZOPYRAN DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-18 | — | — | WO | disclosed |
| US-4908378-A | Benzopyran derivatives and antihypertensive use thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0095316-B1 | PHARMACEUTICALLY ACTIVE AMINOBENZOPYRANS | BEECHAM GROUP PLC (GB) | 1986-12-03 | — | — | EP | disclosed |
| US-4568692-A | LOWERING BLOOD PRESSURE | BEECHAM GROUP P.L.C. | 1986-02-04 | — | — | US | disclosed |
| US-4481214-A | 4-Acylaminobenzopyrans useful as anti-hypertensive agents | BEECHAM GROUP P.L.C. (GB) | 1984-11-06 | — | — | US | disclosed |
| EP-0095316-A1 | Pharmaceutically active aminobenzopyrans | BEECHAM GROUP PLC (GB) | 1983-11-30 | — | — | EP | disclosed |
| EP-0028449-B1 | CHROMANOL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION COMPRISING THEM | BEECHAM GROUP PLC (GB) | 1983-07-20 | — | — | EP | disclosed |
| EP-0028064-B1 | CHROMANOL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION COMPRISING THEM | BEECHAM GROUP PLC (GB) | 1983-07-20 | — | — | EP | disclosed |
| US-4366163-A | Anti-hypertensive chromanol derivatives | BEECHAM GROUP LIMITED (GB) | 1982-12-28 | — | — | US | disclosed |
| EP-0028449-A1 | Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them | BEECHAM GROUP PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | MYD88, MYADM, CD14 | TLR3 34/4885HIF1A 417/4885EPAS1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.